Brokers Offer Predictions for EPRX Q2 Earnings

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Equities researchers at HC Wainwright issued their Q2 2026 earnings per share estimates for Eupraxia Pharmaceuticals in a report released on Tuesday, March 17th. HC Wainwright analyst B. Folkes forecasts that the company will post earnings per share of ($0.20) for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ Q4 2026 earnings at ($0.21) EPS and FY2030 earnings at $0.17 EPS.

A number of other research firms have also weighed in on EPRX. Lifesci Capital upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 11th. Zacks Research cut shares of Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. Cantor Fitzgerald raised their price objective on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a report on Thursday, January 15th. Finally, Wall Street Zen cut shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Eupraxia Pharmaceuticals Stock Performance

Shares of EPRX opened at $7.60 on Wednesday. Eupraxia Pharmaceuticals has a 1 year low of $2.68 and a 1 year high of $9.32. The stock has a market capitalization of $273.30 million, a PE ratio of -7.38 and a beta of 1.27. The stock has a 50-day simple moving average of $8.28 and a 200-day simple moving average of $6.88.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.21).

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Guardian Wealth Advisors LLC NC purchased a new position in Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $76,000. Aptus Capital Advisors LLC purchased a new stake in shares of Eupraxia Pharmaceuticals during the 4th quarter worth approximately $76,000. Quadrature Capital Ltd acquired a new position in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at $61,000. TCI Wealth Advisors Inc. acquired a new position in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at $65,000. Finally, Integrated Wealth Concepts LLC purchased a new position in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at $71,000.

Eupraxia Pharmaceuticals News Summary

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and an $11.00 price target on EPRX — this provides a clear bullish endorsement that can support the share price. Read More.
• Positive Sentiment: Lifesci Capital maintained a “Strong-Buy” stance on the stock, signaling continued institutional conviction despite model changes. Read More.
• Neutral Sentiment: HC Wainwright published detailed quarterly and multi‑year EPS projections (Q1–Q4 2026 and out-year forecasts through FY2030), giving investors updated guidance to model future cash needs and valuation — useful but not immediately directional. Read More.
• Negative Sentiment: Zacks Research downgraded EPRX from “Hold” to “Strong Sell,” which can pressure sentiment and trigger selling by model-driven funds or cautious retail investors. Read More.
• Negative Sentiment: HC Wainwright significantly cut EPS forecasts across multiple years (notably FY2026–FY2029 and FY2028), worsening near‑term profitability expectations and raising concerns about cash burn or longer timelines to commercialization. That reduction in earnings outlook is a substantive negative for valuation. Read More.
• Negative Sentiment: Lifesci Capital trimmed its FY2026 EPS estimate (from -$0.75 to -$0.88) — a deterioration in near-term forecasts that may offset some of the positive signal from its “Strong-Buy” rating. Read More.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.